Generare Bioscience SAS, a Paris-based biotech firm, has raised $23.2 million in a Series A round co-led by Alven and Daphni. Founded in 2023, the company specializes in uncovering previously unknown small molecules from microbial genomes - a vast, untapped reservoir of chemical diversity.
The pharmaceutical industry has long been constrained by a narrow pool of recycled chemistry. Generare breaks this barrier by extracting molecular data evolution spent 3 billion years refining. An estimated 97% of genomic chemical information remains unread - until now.
In 2025 alone, Generare discovered over 200 novel molecules - more than all other AI drug discovery firms combined. The company plans to scale capacity tenfold by 2027, targeting more than 2,000 new molecules annually, with a long-term goal of exceeding 10,000.
"The bottleneck isn’t algorithms - it’s the absence of genuinely novel data," said CEO Guillaume Vandenesch. "We’re building the largest proprietary library of cryptic small molecules."
Generare will double its team of 25 computational biologists, chemists, and engineers to accelerate discovery.